Page 24 - Towards personalized therapy for metastatic prostate cancer: technical validation of [18F]fluoromethylcholine

Chapter 1
REFERENCES
1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90
2. Ferlay J, Steliarova-Foucher, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe:
estimates of 40 countries in 2012. Eur J Cancer. 2013;49:1374–1403
3. Mottet N, Bellmunt J, Briers E, et al. EAU guidelines on prostate cancer. 2015; http://uroweb.org/wp-content/
uploads/09-Prostate-Cancer_LR.pdf
4. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and
prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–1520
5. Michielsen DP, Braeckman JG and Denis L. Cabazitaxel for the treatment of prostate cancer. Expert Opin
Pharmacother. 2011;12:977–982
6. Tannock IF, De Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med. 2004;351:1502–1512
7. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic
castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Lancet. 2010;376:1147–1154
8. Paller CJ and Antonarakis ES. Cabazitaxel: A novel second-line treatment for metastatic castration-resistant
prostate cancer. Drug Des Devel Ther. 2011;5:117–124
9. Parente P, Parnis F and Gurney H. Emerging and second line therapies for the management of metastatic
castration-resistant prostate cancer: The Australian perspective. Asia-Pac J Clin Oncol. 2012;8:31–42
10. Higano CS and Crawford ED. New and emerging agents for the treatment of castration-resistant prostate
cancer. Urol Oncol. 2011;29(6 Suppl):S1–S8
11. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer:
a phase 1–2 study. Lancet. 2010;75:1437–1446
12. Feldman BJ and Feldman D. The development of androgen-independent prostate cancer. Nature Rev Cancer.
2001;1:34–45
13. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant
prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-
controlled phase 3 study. Lancet Oncol. 2012;13:983–992
14. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous
chemotherapy. N Engl J Med. 2013;368:138–148
15. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy.
N Engl J Med. 2012;367:1187–1197
16. Beer TM, Armstrong AJ, Rathkoph DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy.
N Engl J Med. 2014;371:424–433
17. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate
cancer. N Engl J Med. 2010;363:411–422
18. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N
Engl J Med. 2013;369:213–223
19. Bray F, Lortet-Tieulent J, Ferlay J, et al. Prostate cancer incidence and mortality trends in 37 European
countries: an overview. Eur J Cancer. 2010;46:3040–3052
20. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis,
and local treatment with curative intent-update 2013. Eur Urol. 2014;65:124–137
21. Schwarzenbock S, Souvatzoglou M and Krause BJ. Choline PET and PET/CT in primary diagnosis and staging
of prostate cancer. Theranostics. 2012;2:318–330
22. Schiepers C and Dahlbom M. Molecular imaging in oncology: the acceptance of PET/CT and the emergence
of MR/PET imaging. Eur Radiol. 2011;21:548–554
23. Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl
Med. 2008;49:480–508
24. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of
lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.
J Clin Oncol. 2007;25:571–578
25. Lonsdale MN and Beyer T. Dual-modality PET/CT instrumentation – Today and tomorrow. Eur J Radiol.
2010;73:452–460
26. Zaidi H and Alavi A. Current trends in PET and combined (PET/CT and PET/MR) systems design. PET Clin.
2007;109–123
22